12/1
09:02 pm
eols
Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.
Medium
Report
Evolus (NASDAQ:EOLS) was given a new $19.00 price target on by analysts at Mizuho.
11/27
08:01 am
eols
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability [Yahoo! Finance]
Low
Report
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability [Yahoo! Finance]
11/19
02:55 pm
eols
The Dr. Randi Show Podcast, Sponsored by NewBeauty, Ranks in the Top 10% Globally for Conversations in Aesthetics, Beauty, Wellness & Medicine [Yahoo! Finance]
Low
Report
The Dr. Randi Show Podcast, Sponsored by NewBeauty, Ranks in the Top 10% Globally for Conversations in Aesthetics, Beauty, Wellness & Medicine [Yahoo! Finance]
11/14
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/12
10:05 am
eols
Moxie Announces Aesthetic Business Advisory Board and Scale Society Community to Shape the Next Era of Aesthetic Medicine
Low
Report
Moxie Announces Aesthetic Business Advisory Board and Scale Society Community to Shape the Next Era of Aesthetic Medicine
11/8
04:18 pm
eols
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/6
10:22 am
eols
Evolus (EOLS) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Evolus (EOLS) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/5
04:05 pm
eols
Evolus Reports Third Quarter 2025 Financial Results
Medium
Report
Evolus Reports Third Quarter 2025 Financial Results
10/28
08:00 am
eols
Evolus to Participate in 2025 Stifel Healthcare Conference
Low
Report
Evolus to Participate in 2025 Stifel Healthcare Conference
10/22
08:00 am
eols
Evolus to Report Third Quarter Financial Results on November 5, 2025
Low
Report
Evolus to Report Third Quarter Financial Results on November 5, 2025
10/14
12:13 pm
eols
Evolus (NASDAQ:EOLS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Evolus (NASDAQ:EOLS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/10
04:49 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
10/10
04:05 pm
eols
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/8
09:18 am
eols
Exfluential Wins "Best Enterprise or B2B Technology Innovation" at Octane's 2025 High Tech Awards [Yahoo! Finance]
Low
Report
Exfluential Wins "Best Enterprise or B2B Technology Innovation" at Octane's 2025 High Tech Awards [Yahoo! Finance]
10/1
08:30 am
eols
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19 [Yahoo! Finance]
Low
Report
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19 [Yahoo! Finance]
9/22
09:23 am
eols
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch [Yahoo! Finance]
Low
Report
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch [Yahoo! Finance]
9/22
09:03 am
eols
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
Low
Report
Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch
9/20
09:53 am
eols
While shareholders of Evolus (NASDAQ:EOLS) are in the black over 5 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Low
Report
While shareholders of Evolus (NASDAQ:EOLS) are in the black over 5 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
9/18
11:42 am
eols
Japan Botulinum Toxin Market Outlook Report 2025-2038: Growth is Supported by Clinical Trials, Local Production, and Strong Regulatory Frameworks [Yahoo! Finance]
Low
Report
Japan Botulinum Toxin Market Outlook Report 2025-2038: Growth is Supported by Clinical Trials, Local Production, and Strong Regulatory Frameworks [Yahoo! Finance]
9/12
05:30 pm
eols
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/8
11:52 am
eols
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $18.00 price target on the stock.
Low
Report
Evolus (NASDAQ:EOLS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $18.00 price target on the stock.
9/8
09:00 am
eols
Evolus appoints Tatjana Mitchell as chief financial officer [Seeking Alpha]
Low
Report
Evolus appoints Tatjana Mitchell as chief financial officer [Seeking Alpha]
9/8
08:30 am
eols
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
Low
Report
Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer